4.17
Schlusskurs vom Vortag:
$4.10
Offen:
$4
24-Stunden-Volumen:
7.65M
Relative Volume:
1.68
Marktkapitalisierung:
$835.41M
Einnahmen:
$314.00K
Nettoeinkommen (Verlust:
$-40.23M
KGV:
-14.89
EPS:
-0.28
Netto-Cashflow:
$-84.71M
1W Leistung:
+16.81%
1M Leistung:
+53.87%
6M Leistung:
+169.03%
1J Leistung:
+193.66%
Atai Life Sciences N V Stock (ATAI) Company Profile
Firmenname
Atai Life Sciences N V
Sektor
Branche
Telefon
49 89 2153 9035
Adresse
WALLSTRASSE 16, BERLIN
Vergleichen Sie ATAI mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
ATAI
Atai Life Sciences N V
|
4.17 | 869.79M | 314.00K | -40.23M | -84.71M | -0.28 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
673.80 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Atai Life Sciences N V Stock (ATAI) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-07-29 | Eingeleitet | Oppenheimer | Outperform |
2024-11-18 | Bestätigt | H.C. Wainwright | Buy |
2024-04-03 | Hochstufung | Maxim Group | Hold → Buy |
2022-11-01 | Eingeleitet | Loop Capital | Buy |
2021-11-30 | Eingeleitet | Maxim Group | Buy |
2021-11-11 | Eingeleitet | ROTH Capital | Buy |
2021-10-18 | Eingeleitet | H.C. Wainwright | Buy |
2021-09-01 | Eingeleitet | Jefferies | Buy |
2021-07-13 | Eingeleitet | Berenberg | Buy |
2021-07-13 | Eingeleitet | Canaccord Genuity | Buy |
2021-07-13 | Eingeleitet | Cantor Fitzgerald | Buy |
2021-07-13 | Eingeleitet | Citigroup | Buy |
2021-07-13 | Eingeleitet | Cowen | Outperform |
2021-07-13 | Eingeleitet | Credit Suisse | Outperform |
2021-07-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
2021-07-08 | Eingeleitet | Aegis Capital | Buy |
Alle ansehen
Atai Life Sciences N V Aktie (ATAI) Neueste Nachrichten
What is the risk reward ratio of investing in Atai Life Sciences N.V. stockPre Market Forecasts For Smart Trading - jammulinksnews.com
H.C. Wainwright Lifts PT on Atai Life Sciences (ATAI) to $15 From $10 - Insider Monkey
AbbVie in Talks to Acquire Gilgamesh in $1 Billion Deal - Bloomberg
H.C. Wainwright raises atai Life Sciences stock price target to $15 on BPL-003 potential - Investing.com Australia
This IonQ Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Published on: 2025-07-30 03:07:04 - metal.it
What makes Atai Life Sciences N.V. stock price move sharplySwing Setup With Technical Confirmation Explained - metal.it
This Atai Life Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday - Benzinga
Oppenheimer initiates atai Life Sciences stock with Outperform rating By Investing.com - Investing.com South Africa
Oppenheimer initiates atai Life Sciences stock with Outperform rating - Investing.com
Published on: 2025-07-29 09:29:36 - metal.it
Atai: Inidascamine Trial Failure Doesn't Matter In Main Psychedelic Pipeline Focus (ATAI) - Seeking Alpha
ATAI Life Sciences Surges Amidst Market Uncertainty - StocksToTrade
Why Is ATAI Life Sciences Stock Trading Lower On Monday? - Benzinga
ATAI Life Sciences (ATAI) Stock Plunge on Trial Failure News - Yahoo Finance
ATAI Life Sciences, Revvity And Other Big Stocks Moving Lower In Monday's Pre-Market Session - 富途牛牛
Why Celcuity Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket - Benzinga
What are analysts’ price targets for Atai Life Sciences N.V. in the next 12 monthsUnstoppable trading performance - jammulinksnews.com
Nucor, Waste Management And 3 Stocks To Watch Heading Into Monday - Benzinga
What is Atai Life Sciences N.V. company’s growth strategyGet insider insights into market trends - jammulinksnews.com
What are Atai Life Sciences N.V. company’s key revenue driversExceptional stock performance - jammulinksnews.com
How volatile is Atai Life Sciences N.V. stock compared to the marketBuild wealth steadily with proven strategies - jammulinksnews.com
Why Atai Life Sciences N.V. stock attracts strong analyst attentionFree Access to Community - metal.it
Atai Life Sciences (ATAI) Shares Drop 12% After Schizophrenia Dr - GuruFocus
Atai Life Sciences shares fall 14.29% after-hours as schizophrenia drug fails to meet main endpoint. - AInvest
Atai Life Sciences down 12% after hours on mid-stage failure of schizophrenia asset - Seeking Alpha
Published on: 2025-07-26 00:30:53 - PrintWeekIndia
ATAI Life Sciences stock falls after Recognify’s CIAS drug misses endpoint - Investing.com UK
Clinical Trial Reveals Promising Signals for New Schizophrenia Cognitive Drug Despite Missed Endpoint - Stock Titan
Canaccord Increases Atai Life Sciences (ATAI) PT, Keeps Buy Rating - Insider Monkey
10 Best Performing Penny Stocks So Far in 2025 - Insider Monkey
Is Atai Life Sciences N.V. a good long term investmentBreakout profit opportunities - PrintWeekIndia
Canaccord Genuity Lifts Atai Life Sciences N.V. (ATAI)’s Price Target To $12, Maintains Buy Rating - MSN
What drives Atai Life Sciences N.V. stock priceExponential return rates - jammulinksnews.com
What analysts say about Atai Life Sciences N.V. stockMassive wealth growth - Autocar Professional
atai Life Sciences (ATAI) Upgraded to Strong Buy: Here's Why - MSN
5-HT2 Agonist Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, Mechanism of Action, Route of Administration, and Companies by DelveInsight - The Globe and Mail
atai Life Sciences Bets Big On Psychedelics For Mental Health - Finimize
ATAI Impresses, CDTX Navigates With Confidence, MTSR Builds Momentum, COGT Keeps Scaling The Summit… - RTTNews
Finanzdaten der Atai Life Sciences N V-Aktie (ATAI)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):